ArticleWorld journal of pediatrics : WJP2025
Pediatric complex chronic and life-limiting conditions in the Basque public health system: cross-sectional prevalence study.
Article in World journal of pediatrics : WJP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trend analysis and Bayesian projection of childhood life-limiting conditions in Korea: insights into incidence and mortality.BMJ paediatrics open · 2026Observational
- Identification and characteristics of children with complex chronic diseases in the paediatric ward of a tertiary hospital: a prospective study.European journal of pediatrics · 2026Article
- How many children have palliative care needs and which of them are less likely to be actively seen by services? A cross-sectional analysis of survey data.BMJ paediatrics open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival of children and adolescents with complex chronic conditions (CCCs) and/or life-limiting or life-threatening conditions (LLCs) is increasing, while estimating their prevalence is complex and limited. This study aims to describe the prevalence of CCCs and/or LLC in children and adolescents and their profile in a European public health system.
methodsThis was a descriptive cross-sectional study of the whole pediatric population (< 19 years) registered in the Basque Public Health System (BPHS) in May 2022. Sociodemographic data and active diagnoses were extracted from the electronic medical records. The Pediatric Medical Complexity Algorithm v3.2 was used to identify children and adolescents with CCC and the Hain Directory of Life-Limiting Conditions, modified ad hoc for patients with LLC.
resultsA total of 377,349 children and adolescents were detected in the BPHS. The prevalence of children and adolescents with CCC was 681 per 10,000. It was higher in males and increased progressively with age. The most affected systems were neurological (39.9%), respiratory (37.2%), mental health (28.1%), musculoskeletal (20.7%) and metabolic (19.7%) systems. The prevalence of children and adolescents with LLC was 90.7 per 10,000. It was the highest in children under one year of age and was slightly higher among males. The most common conditions were congenital malformations and chromosomal anomalies (37.7%), oncological (18.3%), neurological (16.1%) and metabolic diseases (6.5%). Among children and adolescents with LLC, 72% also had CCC. The prevalence of LCC and/or CCC was greater in children and adolescent patients with lower socioeconomic status.
conclusionsThe prevalence of CCC and/or LLC in children with BPHS was high. A considerable proportion of children with LLC also met the criteria for CCC. These findings may help allocate available healthcare resources equitably and efficiently to provide comprehensive care for patients and their families.
Indexed as
Identifiers
39934525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.